Organon & Co. stockholders approved the company’s proposed merger with Sun Pharmaceutical’s U.S. holding company at a special meeting held virtually on July 23, 2026, clearing a key shareholder hurdle for the transaction. The vote concerned the Agreement and Plan of Merger dated April 26, 2026, among Organon, Sun Pharmaceutical Holdings USA, Inc., and Sun Pharma America, Inc., a wholly owned subsidiary of Sun Pharma USA. Sun Pharmaceutical Industries Limited, Sun Pharma Canada Inc. and Sun Pharma (Netherlands) B.V. are also parties for certain specified provisions. Under the agreement, Sun Pharma America will merge with and into Organon, with Organon surviving as a wholly owned subsidiary of Sun Pharma USA. As of the June 15, 2026 record date, Organon had 262,609,433 shares of common stock outstanding and entitled to vote. At the special meeting, 195,675,859 shares were represented virtually or by proxy, equal to 74.51% of the company’s total voting power and sufficient for a quorum. Each Organon common share carried one vote. The merger agreement was adopted by a large majority of the shares voted: 192,776,552 votes were cast in favor, 2,573,118 against and 326,189 abstained. The company also reported that stockholders approved, on a non-binding advisory basis, merger-related compensation that may be paid or become payable to Organon’s named executive officers. That proposal received 185,141,986 votes for, 9,553,830 against and 980,043 abstentions. The filing reports the results under Item 5.07, “Submission of Matters to a Vote of Security Holders.” The approval is significant because stockholder adoption of the merger agreement is typically one of the central conditions required to complete a public-company merger. The document does not provide closing timing, merger consideration per share or other transaction conditions beyond the voting results and the parties to the agreement.